dc.contributor.author | Karagoz, Filiz | |
dc.contributor.author | Canbaz, SEVGİ | |
dc.contributor.author | MUTLU, Hulya Savas | |
dc.contributor.author | Aydin, Oguz | |
dc.contributor.author | Baris, Sancar | |
dc.date.accessioned | 2021-03-06T12:55:57Z | |
dc.date.available | 2021-03-06T12:55:57Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | MUTLU H. S. , Aydin O., Baris S., Canbaz S., Karagoz F., "The Expression Frequency of Androgen Receptor, c-erbB2 and CD117 in Acinar Adenocarcinoma of Prostate and Normal Prostate Tissue and It's Clinical Importance", UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, cilt.14, ss.245-250, 2015 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_f6414421-c89b-4d67-b9bd-937ebee3fcef | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/161340 | |
dc.identifier.uri | https://doi.org/10.4274/uob.376 | |
dc.description.abstract | Objective: In the cancer treatment, protein kinase inhibitors targeted at markers such as Her-2/neu (c-erbB2) and c-kit (CD117) are successful approaches. In this study, the expression of c-erbB2 and CD117 in normal prostate tissue as well as with low, moderate and high risk acinar adenocarcinoma of prostate with no androgen-suppression therapy, and, metastatic adenocarcinoma of prostate was investigated and the expression of androgen receptor (AR) was compared with c-erbB2 and CD117. | |
dc.language.iso | eng | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Tıp | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ONKOLOJİ | |
dc.title | The Expression Frequency of Androgen Receptor, c-erbB2 and CD117 in Acinar Adenocarcinoma of Prostate and Normal Prostate Tissue and It's Clinical Importance | |
dc.type | Makale | |
dc.relation.journal | UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY | |
dc.contributor.department | Ondokuz Mayıs Üniversitesi , , | |
dc.identifier.volume | 14 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 245 | |
dc.identifier.endpage | 250 | |
dc.contributor.firstauthorID | 105290 | |